Amarin (AMRN - Free Report) closed at $21.96 in the latest trading session, marking a +0.78% move from the prior day. This move outpaced the S&P 500's daily loss of 1.73%. At the same time, the Dow lost 1.19%, and the tech-heavy Nasdaq lost 2.07%.
Heading into today, shares of the biopharmaceutical company had gained 57.56% over the past month, outpacing the Medical sector's loss of 8.88% and the S&P 500's loss of 7.09% in that time.
Wall Street will be looking for positivity from AMRN as it approaches its next earnings report date. This is expected to be November 1, 2018. In that report, analysts expect AMRN to post earnings of -$0.09 per share. This would mark a year-over-year decline of 125%. Meanwhile, our latest consensus estimate is calling for revenue of $61.50 million, up 29.86% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.42 per share and revenue of $228.93 million, which would represent changes of -68% and +26.41%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for AMRN. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. AMRN currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 89, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Amarin (AMRN - Free Report) closed at $21.96 in the latest trading session, marking a +0.78% move from the prior day. This move outpaced the S&P 500's daily loss of 1.73%. At the same time, the Dow lost 1.19%, and the tech-heavy Nasdaq lost 2.07%.
Heading into today, shares of the biopharmaceutical company had gained 57.56% over the past month, outpacing the Medical sector's loss of 8.88% and the S&P 500's loss of 7.09% in that time.
Wall Street will be looking for positivity from AMRN as it approaches its next earnings report date. This is expected to be November 1, 2018. In that report, analysts expect AMRN to post earnings of -$0.09 per share. This would mark a year-over-year decline of 125%. Meanwhile, our latest consensus estimate is calling for revenue of $61.50 million, up 29.86% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.42 per share and revenue of $228.93 million, which would represent changes of -68% and +26.41%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for AMRN. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. AMRN currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 89, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on AMRN - FREE